Related Experiment Video
Updated: Jan 4, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
Diminished right ventricular function at diagnosis of pulmonary hypertension is associated with mortality in
Gabriel Altit1,2, Shazia Bhombal3, Jeffrey Feinstein4
1Neonatology, McGill University Health Centre, Montreal Children's Hospital, Montreal, Canada.
Insights
Pulmonary hypertension (PH) and right ventricular (RV) dysfunction in premature infants with bronchopulmonary dysplasia (BPD) are linked to mortality. Echocardiography can identify high-risk infants for closer monitoring.
Area of Science:
- Neonatology
- Pediatric Cardiology
- Pulmonary Medicine
Background:
- Pulmonary hypertension (PH) is increasingly recognized in preterm infants, especially those with bronchopulmonary dysplasia (BPD).
- Limited data exist on how PH severity and right ventricular (RV) dysfunction at diagnosis impact outcomes in this population.
Purpose of the Study:
- To evaluate the association between echocardiography measures of cardiac dysfunction and PH severity with mortality in infants with BPD-PH.
- To determine if RV dysfunction and PH severity at diagnosis predict mortality in BPD-PH patients.
Main Methods:
- Retrospective analysis of echocardiography data within three months of PH diagnosis.
- Inclusion of 52 preterm infants with BPD and PH.
- Survival analysis using univariate Cox proportional hazard models.
Main Results:
- 16 out of 52 (31%) infants died during follow-up.
- Multiple echocardiographic measures of PH severity (sPAP/sBP) and RV performance (eccentricity index, TAPSE Z-score, FAC, GLS) were significantly associated with mortality.
- Hazard ratios indicated increased mortality risk with higher PH severity and impaired RV function.
Conclusions:
- PH severity and RV dysfunction at diagnosis are associated with mortality in infants with BPD-PH.
- Thorough RV function evaluation and PH markers in echocardiography can help identify high-risk infants.
- These assessments should be considered standard additions to current 36-week screening for BPD-PH.
Abstract:
Pulmonary vascular disease and resultant pulmonary hypertension (PH) have been increasingly recognized in the preterm population, particularly among patients with bronchopulmonary dysplasia (BPD). Limited data exist on the impact of PH severity and right ventricular (RV) dysfunction at PH diagnosis on outcome. The purpose of this study was to evaluate if echocardiography measures of cardiac dysfunction and PH severity in BPD-PH were associated with mortality. The study is a retrospective analysis of the echocardiography at three months or less from time of PH diagnosis. Survival analysis using a univariate Cox proportional hazard model is presented and expressed using hazard ratios (HR). We included 52 patients with BPD and PH of which 16 (31%) died at follow-up. Average gestational age at birth was 26.3 ± 2.3 weeks. Echocardiography was performed at a median of 43.3 weeks (IQR: 39.0-54.7). The median time between PH diagnosis and death was 117 days (range: 49-262 days). Multiple measures of PH severity and RV performance were associated with mortality (sPAP/sBP: HR 1.02, eccentricity index: HR 2.02, tricuspid annular plane systolic excursion Z-score: HR 0.65, fractional area change: HR 0.88, peak longitudinal strain: HR 1.22). Hence, PH severity and underlying RV dysfunction at PH diagnosis were associated with mortality in BPD-PH patients. While absolute estimation of pulmonary pressures is not feasible in every screening echocardiography, thorough evaluation of RV function and other markers of PH may allow to discriminate the most at-risk population and should be considered as standard add-ons to the current screening at 36 weeks.
More Related Videos
Related Concept Videos
Mitral Stenosis I: Introduction
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Mitral Regurgitation I: Introduction
Heart Failure III: Clinical Manifestations
Mitral Stenosis II: Clinical features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy

